Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel de Castro has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incremental yield of genetic retesting in hypertrophic cardiomyopathy

    by Daniel de Castro, Juan Pablo Ochoa, Ana Isabel Fernández-Ávila, Eva Cabrera-Romero, Juan Antonio Jiménez-Barceló, Jorge Armesto-Rivas, Ángel Bernabé-García, Cristina Gómez-González, Laura Torres-Juan, Ana Briceño-Hinojo, et al.

    Background and Aims: Modern genetic testing in hypertrophic cardiomyopathy (HCM) includes newly described HCM-associated genes and full intronic regions of certain classic sarcomeric genes. This study evaluated genetic retesting in HCM patients with a prior negative test and identified predictors of a positive result to guide retesting. Methods: This multicentre study included patients with HCM who previously had negative next-generation sequencing (NGS)-based genetic testing at four centres. Subjects were retested using an updated NGS-based HCM panel. Results: Of 508 retested HCM patients (median age 70 years; 66.9% male; median maximal left ventricular wall thickness 18 mm; median interval from initial genetic test 6.6 years), 46 (9%) had 48 HCM-related variants: 14 in new HCM-associated genes, 3 in deep intronic MYBPC3 regions, 18 intermediate-effect variants, and 13 (8 reclassified) in classic HCM-associated genes. In multivariable analysis, the presence of late gadolinium enhancement (LGE) [odds ratio (OR) 3.52; 95% confidence interval (CI) 1.38–10.25], the Mayo HCM score (OR 1.46 per 1 point increase; 95% CI 1.08–2.01), and the Toronto HCM score (OR 1.18 per 1 point increase; 95% CI 1.08–1.30) were independent predictors of detecting HCM-related variants at retesting. The diagnostic yields in patients with LGE and a high Toronto score (≥13 points), and with LGE and a high Mayo score (≥4 points), were 80% and 50%, respectively. Conclusions: In patients with HCM and prior negative genetic testing, retesting identified HCM-related variants in 9% of individuals, allowing counselling and risk stratification. Late gadolinium enhancement, combined with the Mayo and Toronto scores, may be used to guide which patients should be prioritized for genetic retesting.

  • Open Access

    Clinical and Subclinical Congestion in Acute Heart Failure: A Multimodal Prognostic Assessment

    by Sara Lozano-Jiménez, Paula Vela-Martín, Alba Martín-Centellas, Daniel de Castro, Cristina Mitroi, Francisco José Hernández-Pérez, Marta Cobo-Marcos, Sergio Martínez-Álvarez, Manuel Gómez-Bueno, Javier Segovia-Cubero, et al.

    Background/Objectives: Congestion is a hallmark of heart failure (HF) and a major determinant of outcomes. Non-invasive tools enable detection of subclinical congestion, but their correlation and prognostic relevance remain incompletely defined. The present study aimed to assess the prevalence, evolution, interrelationships, and prognostic impact of clinical and subclinical congestion markers in patients hospitalized for HF. Methods: This single-centre, prospective cohort study included adults admitted with HF who underwent serial evaluations at admission, 72 h, pre-discharge, early outpatient follow-up and at 6 months. Clinical congestion was assessed using a standardized physical examination score. Subclinical congestion was evaluated using lung ultrasound (LUS), Venous Excess Ultrasound Score (VExUS), and Remote Dielectric Sensing (ReDS). Patients were classified according to the presence of clinical and/or subclinical congestion at discharge. The primary endpoint was a composite of all-cause mortality, HF readmission, or unscheduled visits requiring intravenous diuretics within six months. Results: Ninety-four patients (mean age 74 ± 11 years, 68% male) were included. While clinical congestion improved significantly during hospitalization, approximately 30% of patients remained clinically congested at discharge. Among clinically euvolemic patients, only 47% showed no evidence of subclinical congestion. Correlations between congestion markers were weak to moderate, suggesting complementary pathophysiological information. At discharge, pulmonary B-lines were the strongest predictor of the composite endpoint (hazard ratio [HR] 3.50, 95% CI 1.41–8.72), followed by clinical congestion (HR 2.67, 95% CI 1.13–6.30). Patients with clinical and subclinical congestion exhibited lower event-free survival. Conclusions: Subclinical congestion is common despite apparent clinical euvolemia and is associated with worse outcomes. Integrating clinical assessment with non-invasive congestion markers may improve post-discharge risk stratification in HF.


  • Open Access

    Truncating Variants in TTN are Associated With Primary Atrial Myopathy

    by Daniel de Castro, Diane Fatkin, Enrique Rodriguez‐Rubio, Francois Haddad, Fernando Hernández‐Terciado, Anisha Purohit, Shadi P. Bagherzadeh, Priyanka Nair, Aria Rad, Vikki A. Krysov, et al.

    Background: Truncating TTN variants (TTNtv) are the main genetic cause of dilated cardiomyopathy (DCM) and are independently associated with atrial fibrillation (AF). In DCM, AF usually arises from left atrial (LA) remodeling attributable to left ventricular systolic dysfunction. Whether TTNtv are linked to primary LA dysfunction independent of left ventricular systolic dysfunction remains unclear. Methods: This retrospective, multicenter study evaluated atrial function by strain echocardiography in TTNtv carriers across the left ventricular ejection fraction (LVEF) spectrum and its relationship with AF. Individuals with TTNtv and LVEF ≥50% (TTNtv+/DCM–) were compared with matched healthy controls, and those with LVEF P P P P P =0.200). Conclusions: LA myopathy, detected by strain imaging, appears early in TTNtv+/DCM– individuals and may represent an early phenotypic marker independent of left ventricular systolic dysfunction. When LVEF declines below 50%, atrial dysfunction worsens in parallel. AF was more frequent in TTNtv carriers, supporting further research on LA strain for AF risk stratification within this population.


  • Open Access

    Clinical and Subclinical Congestion in Acute Heart Failure: Prevalence, Evolution, Correlations, and Prognostic Impact

    by Sara Lozano-Jiménez, Paula Vela Martín, Alba Martín Centellas, Daniel de Castro Campos, Cristina Mitroi, Francisco José Hernández-Pérez, Marta Cobo-Marcos, Sergio Martínez-Álvarez, Manuel Gómez-Bueno, Javier Segovia-Cubero, et al.

    Background/Objectives: Congestion is a hallmark of heart failure (HF) and a major determinant of outcomes. Non-invasive tools enable detection of subclinical congestion, but their correlation and prognostic relevance remain incompletely defined. We aimed to assess the prevalence, evolution, interrelationship, and prognostic impact of clinical and subclinical congestion markers in patients hospitalized for HF. Methods: This single-centre, prospective cohort study included adults admitted with HF who underwent serial evaluations at admission, 72 hours, pre-discharge, early outpatient follow-up and at 6-month. Clinical congestion was assessed using a standardized physical examination score. Subclinical congestion was evaluated using lung ultrasound (LUS), Venous Excess Ultrasound Score (VExUS), and Remote Dielectric Sensing (ReDS). Patients were classified according to the presence of clinical and/or subclinical congestion at discharge. The primary endpoint was a composite of all-cause mortality, HF readmission, or unscheduled visits requiring intravenous diuretics within six months of follow-up. Results: Ninety-four patients (mean age 74±11 years, 68% male) were included. While clinical congestion improved significantly during hospitalization, approximately 30% of patients remained clinically congested at discharge. Among clinically euvolemic patients, only 47% showed no evidence of subclinical congestion. Correlations between congestion markers were weak to moderate, suggesting complementary pathophysiological information. At discharge, pulmonary B-lines were the strongest predictor of the composite endpoint (hazard ratio [HR] 3.50, 95% CI 1.41–8.72), followed by clinical congestion (HR 2.67, 95% CI 1.13–6.30). Patients with both clinical and subclinical congestion had the lowest event-free survival, approximately 50% at six months of follow-up (log-rank p = 0.03). Conclusions: Subclinical congestion is common despite apparent clinical euvolemia and is associated with worse outcomes. Integrating clinical assessment with non-invasive congestion markers may improve post-discharge risk stratification and patient management in HF.

  • Prevalence and prognostic impact of subclinical venous congestion in patients hospitalized for acute heart failure

    by Sara Lozano-Jiménez, Cristina García Sebastian, Paula Vela Martín, Belén García Magallón, Alba Martín Centellas, Daniel de Castro, Cristina Mitroi, Susana del Prado Díaz, Francisco José Hernández-Pérez, Marta Jiménez-Blanco Bravo, et al.

    Aims: Congestion is a major cause of hospitalisation in patients with heart failure (HF), and the persistence of congestive signs at discharge is a robust predictor of early readmission. Currently, there is increasing interest in the comprehensive assessment of subclinical congestion, as it can increase residual risk in individuals who appear to be euvolemic. Our aim was to investigate the prevalence and prognostic impact of subclinical venous congestion assessed by ultrasound. Methods and results: This is a two-centre, prospective observational study. Patients admitted for HF between June 2021 and March 2023 were selected. Clinical [physical examination (PE)] and subclinical venous congestion [Venous Excess Ultrasound score (VExUS)] were assessed. The prognostic impact was assessed through a composite endpoint of death from any cause, HF readmissions, or unscheduled visits requiring intravenous diuretic administration at 6-month follow-up. 120 patients were included (62% male, mean age 75 ± 15 years). Congestion parameters decreased during hospitalisation but tended to worsen at the first outpatient visit. At discharge, 24% showed subclinical venous congestion. This group had a significantly higher incidence of adverse outcomes, comparable to those with overt clinical congestion. Subclinical congestion was an independent predictor of the composite endpoint (HR 2.84; 95% CI: 1.01–8.01, P value = 0.048) after adjustment for age, chronic kidney disease, NYHA class at admission, and NT-proBNP level at discharge. Conclusion: Clinical and subclinical congestion decreased during hospitalisation but worsened shortly after discharge. A quarter of patients had residual venous congestion, which was associated with a worse prognosis at 6 months.


  • Traboulsi syndrome

    by Daniel de Castro, David Pujol-Pocull, Fernando Domínguez

    A 35-year-old man presented to the hospital with chest pain. He had a history of crystalline subluxation (Panel A), recurrent sprains, and bilateral inguinal hernia. Computed tomography angiography (Panels B and C) showed severe dilation of the ascending aorta (maximum diameter of 103 mm in axial plane) and ruled out dissection. An echocardiogram evidenced severe aortic regurgitation (see Supplementary data online, Video S1). The patient displayed facial dysmorphic features (Panel D) and lacked a family history of aortopathy or consanguinity. A Bentall procedure was performed successfully. Genetic testing (next-generation sequencing panel of 81 genes related to aortic diseases) did not detect any pathogenic variant, despite high suspicion of Marfan syndrome. Further trio-genome sequencing, including his parents, identified in the patient homozygosity (Panel E, arrow) for the c.1110_1112dup (p.Tyr371*) variant in the aspartate-β-hydroxylase gene (ASPH), confirming Traboulsi syndrome. Traboulsi syndrome1 is an autosomal recessive multisystem disorder characterized by features of connective tissue disorders, particularly those observed in Marfan syndrome, such as ectopia lentis, aortic dilatation, pectus excavatum, mitral valve prolapse, joint hypermobility, pes planus, or recurrent pneumothorax. Despite initial negative genetic testing, further advanced sequencing techniques were crucial in diagnosing this rare condition,2 highlighting the importance of comprehensive genetic evaluation in syndromic aortopathies.


  • Open Access

    Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction

    by Almudena Amor-Salamanca, Alfredo Santana Rodríguez, Hazhee Rasoul, José F. Rodríguez-Palomares, Oana Moldovan, Thomas Morris Hey, María Gallego Delgado, David López Cuenca, Daniel de Castro Campos, María Teresa Basurte-Elorz, et al.

    BACKGROUND: Less than 40% of patients with dilated cardiomyopathy (DCM) have a pathogenic/likely pathogenic genetic variant identified. TBX20 has been linked to congenital heart defects; although an association with left ventricular noncompaction (LVNC) and DCM has been proposed, it is still considered a gene with limited evidence for these phenotypes. This study sought to investigate the association between the TBX20 truncating variant ( TBX20tv ) and DCM/LVNC. METHODS: TBX20 was sequenced by next-generation sequencing in 7463 unrelated probands with a diagnosis of DCM or LVNC, 22 773 probands of an internal comparison group (hypertrophic cardiomyopathy, channelopathies, or aortic diseases), and 124 098 external controls (individuals from the gnomAD database). Enrichment of TBX20tv in DCM/LVNC was calculated, cosegregation was determined in selected families, and clinical characteristics and outcomes were analyzed in carriers. RESULTS: TBX20tv was enriched in DCM/LVNC (24/7463; 0.32%) compared with internal (1/22 773; 0.004%) and external comparison groups (4/124 098; 0.003%), with odds ratios of 73.23 (95% CI, 9.90–541.45; P P TBX20tv was cosegregated with DCM/LVNC phenotype in 21 families for a combined logarythm of the odds score of 4.53 (strong linkage). Among 57 individuals with TBX20tv (49.1% men; mean age, 35.9±20.8 years), 41 (71.9%) exhibited DCM/LVNC, of whom 14 (34.1%) had also congenital heart defects. After a median follow-up of 6.9 (95% CI, 25–75:3.6–14.5) years, 9.7% of patients with DCM/LVNC had end-stage heart failure events and 4.8% experienced malignant ventricular arrhythmias. CONCLUSIONS: TBX20tv is associated with DCM/LVNC; congenital heart defect is also present in around one-third of cases. TBX20tv -associated DCM/LVNC is characterized by a nonaggressive phenotype, with a low incidence of major cardiovascular events. TBX20 should be considered a definitive gene for DCM and LVNC and routinely included in genetic testing panels for these phenotypes.


  • Experience and insights from a prolonged electrocardiographic monitorization with a wearable system after an embolic stroke of unknown source

    by Daniel de Castro, Jorge Toquero‐Ramos, Diego Jiménez‐Sánchez, Eusebio García‐Izquierdo, Víctor Castro‐Urda, Cristina Aguilera‐Agudo, Fernando Domínguez, Daniel García‐Rodríguez, Paula Vela‐Martín, Paloma Remior, et al.

    Embolic cerebrovascular events that remain of unknown etiology after a thorough diagnostic evaluation, are known as Embolic Strokes of Undetermined Source (ESUS). Subclinical atrial fibrillation (AF) represents a significant underlying cause of ESUS. Our aims were to examine the overall diagnostic yield of a prolonged cardiac monitoring wearable system (PCMw) after an ESUS to detect AF and factors associated with it, including the time frame from the ESUS event to PCMw initiation. Additionally, to evaluate the frequency of unexpected arrhythmic events (UAE) and their prognostic implications. We retrospectively analyzed 200 ECG recordings (3-leads, 30 days duration) by means of a PCMw in patients with an ESUS to detect AF lasting longer than 30 s, between 2017 and 2021. UAE were defined as arrhythmia events that were not correlated to the main reason of prolonged cardiac monitoring. AF was detected in 21 patients (10.5%). Patients with AF had more left atrial enlargement (OR = 4.22 [1.59-6.85]; p = .01) and atrial arrythmias in the initial 24-h Holter during hospitalization (OR = 5.73 [2.03-16.49]; p = .001). The detection of AF was significatively higher if the PCMw was worn within the first 30 days after the ESUS compared to beyond 30 days (17% vs. 10.3%; p = .002). Fifty three patients (26.5%) had UAE during PCMw. In six of them these findings led to targeted treatment. PCMw represents a feasible non-invasive device that could reliably detect subclinical AF episodes after an ESUS. Diagnostic yield was significatively higher when used within the first 30 days after the event, especially in selected patients. UAE were common, but did not impact prognosis.


  • Ventricular hypertrophy and family history of cardiac amyloidosis: is it always what it seems?

    by Daniel de Castro, Basilio Angulo-Lara, David Pujol-Pocull, Carlos Collado-Macián, Esther González-López


  • Open Access

    Hemolytic Anemia After an Aortic Dissection Treated With a Valve-Sparing Aortic Root Replacement

    by Daniel de Castro, Juan E. de Villarreal-Soto, Elsa Carolina Ríos, Sara Lozano, Javier Ortega-Marcos, Alberto Forteza-Gil